-
1
-
-
0019972810
-
The cholinergic hypothesis of geriatric memory dysfunction
-
Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408-414.
-
(1982)
Science
, vol.217
, pp. 408-414
-
-
Bartus, R.T.1
Dean III, R.L.2
Beer, B.3
Lippa, A.S.4
-
2
-
-
0022645755
-
The cholinergic hypothesis ten years on
-
Perry EK. The cholinergic hypothesis ten years on. Br Med Bull. 1986;42:63-69.
-
(1986)
Br Med Bull
, vol.42
, pp. 63-69
-
-
Perry, E.K.1
-
3
-
-
0026536517
-
Treatment strategies for Alzheimer's disease
-
Bowen DM, Francis PT, Pangalos MN, Stephens PH, Procter AW. Treatment strategies for Alzheimer's disease. Lancet. 1992;339: 132-133.
-
(1992)
Lancet
, vol.339
, pp. 132-133
-
-
Bowen, D.M.1
Francis, P.T.2
Pangalos, M.N.3
Stephens, P.H.4
Procter, A.W.5
-
4
-
-
0022457840
-
Nicotinic acetylcholine binding sites in Alzheimer's disease
-
Whitehouse PJ, Martino AM, Antuono PG, et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 1986;371:146-151.
-
(1986)
Brain Res
, vol.371
, pp. 146-151
-
-
Whitehouse, P.J.1
Martino, A.M.2
Antuono, P.G.3
-
5
-
-
0030751425
-
Nicotinic acetylcholine involvement in Alzheimer's and Parkinson's disease: Implications for therapeutics
-
Newhouse PA, Potter A, Levin ED. Nicotinic acetylcholine involvement in Alzheimer's and Parkinson's disease: implications for therapeutics. Drugs Aging. 1997;11:206-228.
-
(1997)
Drugs Aging
, vol.11
, pp. 206-228
-
-
Newhouse, P.A.1
Potter, A.2
Levin, E.D.3
-
6
-
-
0035826771
-
Practice parameter: Management of dementia (an evidence-based review)
-
Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Neurology. 2001;56: 1154-1166.
-
(2001)
Neurology
, vol.56
, pp. 1154-1166
-
-
Doody, R.S.1
Stevens, J.C.2
Beck, C.3
-
7
-
-
0036063785
-
The tolerability and safety of cholinesterase inhibitors in the treatment of dementia
-
Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl. 2002;127:45-63.
-
(2002)
Int J Clin Pract Suppl
, vol.127
, pp. 45-63
-
-
Inglis, F.1
-
8
-
-
33645735618
-
Donepezil in Alzheimer's disease: An evidence-based review of its impact on clinical and economic outcomes
-
Knowles J. Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes. Core Evid. 2006;1:195-219.
-
(2006)
Core Evid
, vol.1
, pp. 195-219
-
-
Knowles, J.1
-
9
-
-
3042550038
-
Donepezil for Alzheimer's disease in clinical practice -the DONALD study
-
Froelich L, Gertz HJ, Heun R, et al. Donepezil for Alzheimer's disease in clinical practice -the DONALD study. Dement Geriatr Cogn Disord. 2004;18:37-43.
-
(2004)
Dement Geriatr Cogn Disord
, vol.18
, pp. 37-43
-
-
Froelich, L.1
Gertz, H.J.2
Heun, R.3
-
11
-
-
3042567016
-
AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial
-
Courtney C, Farrell D, Gray R, et al. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004;363: 2105-2115.
-
(2004)
Lancet
, vol.363
, pp. 2105-2115
-
-
Courtney, C.1
Farrell, D.2
Gray, R.3
-
13
-
-
33644826545
-
Differential effects or rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer's disease: 18-month, randomized, open-label trial
-
Cumbo E. Differential effects or rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer's disease: 18-month, randomized, open-label trial. Prim Care Community Psychiatr. 2005;10:95-102.
-
(2005)
Prim Care Community Psychiatr
, vol.10
, pp. 95-102
-
-
Cumbo, E.1
-
14
-
-
84862615890
-
The cost-effectiveness of donepezil and rivastigmine in the treatment of Alzheimer's disease in Thailand private hospital
-
Pattanaprateep O, Phongchareonsuk P, Chaikledkaew U. The cost-effectiveness of donepezil and rivastigmine in the treatment of Alzheimer's disease in Thailand private hospital. Value Health. 2005;8:314-815.
-
(2005)
Value Health
, vol.8
, pp. 314-815
-
-
Pattanaprateep, O.1
Phongchareonsuk, P.2
Chaikledkaew, U.3
-
15
-
-
14744273100
-
Treatment of behavioural and psychiatric symptoms in dementia: Implications of recent safety warnings
-
Bullock R. Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Curr Med Res Opin. 2005;21:1-10.
-
(2005)
Curr Med Res Opin
, vol.21
, pp. 1-10
-
-
Bullock, R.1
-
16
-
-
84862619683
-
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No 111): A systematic review and economic model
-
Bond M, Rogers G, Peters J, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No 111): a systematic review and economic model. Health Technol Assess. 2012;16:1-470.
-
(2012)
Health Technol Assess
, vol.16
, pp. 1-470
-
-
Bond, M.1
Rogers, G.2
Peters, J.3
-
17
-
-
33644974191
-
Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: A double-blind, head-to-head, randomized pilot study
-
Ancoli-Israel S, Amatniek J, Ascher S, Sadik K, Ramaswamy K. Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study. Alzheimer Dis Assoc Disord. 2005;19:240-245.
-
(2005)
Alzheimer Dis Assoc Disord
, vol.19
, pp. 240-245
-
-
Ancoli-Israel, S.1
Amatniek, J.2
Ascher, S.3
Sadik, K.4
Ramaswamy, K.5
-
18
-
-
84863669083
-
Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: A systematic review
-
Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open. 2012;2:e000917.
-
(2012)
BMJ Open
, vol.2
-
-
Farrimond, L.E.1
Roberts, E.2
McShane, R.3
-
19
-
-
84863989904
-
Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: A post-marketing surveillance study
-
Clerici F, Vanvacore N, Elia A, et al. Memantine effects on behaviour in moderately severe to severe Alzheimer's disease: a post-marketing surveillance study. Neurol Sci. 2012;33:23-31.
-
(2012)
Neurol Sci
, vol.33
, pp. 23-31
-
-
Clerici, F.1
Vanvacore, N.2
Elia, A.3
-
20
-
-
41049104686
-
Current pharmacologic treatment of dementia: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians
-
Qaseem A, Snow V, Cross TJ Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148:370-378.
-
(2008)
Ann Intern Med
, vol.148
, pp. 370-378
-
-
Qaseem, A.1
Snow, V.2
Cross Jr., T.J.3
-
21
-
-
77956666900
-
Dimebon disappointment
-
Jones WR. Dimebon disappointment. Alzheimers Res Ther. 2010;2:25.
-
(2010)
Alzheimers Res Ther
, vol.2
, pp. 25
-
-
Jones, W.R.1
-
22
-
-
84862806815
-
Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors
-
Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther. 2012;134:8-25.
-
(2012)
Pharmacol Ther
, vol.134
, pp. 8-25
-
-
Tayeb, H.O.1
Yang, H.D.2
Price, B.H.3
Tarazi, F.I.4
-
23
-
-
79955444505
-
A phase II trial of huperzine A in mild to moderate Alzheimer disease
-
Rafii MS, Walsh S, Little JT, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76:1389-1394.
-
(2011)
Neurology
, vol.76
, pp. 1389-1394
-
-
Rafii, M.S.1
Walsh, S.2
Little, J.T.3
-
24
-
-
84858195896
-
New pharmacological strategies for treatment of Alzheimer's disease: Focus on disease-modifying drugs
-
Salomone S, Caraci F, Leggio GM, et al. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease-modifying drugs. Br J Clin Pharmacol. 2012;73:504-517.
-
(2012)
Br J Clin Pharmacol
, vol.73
, pp. 504-517
-
-
Salomone, S.1
Caraci, F.2
Leggio, G.M.3
-
25
-
-
84857709982
-
Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment
-
Weinreb O, Amit T, Bar-Am O, Youdim MB. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012;13:483-494.
-
(2012)
Curr Drug Targets
, vol.13
, pp. 483-494
-
-
Weinreb, O.1
Amit, T.2
Bar-Am, O.3
Youdim, M.B.4
-
26
-
-
0025899041
-
Amyloid hypothesis deposition as the central event in the aetiology of Alzheimer's disease
-
Hardy J, Akksop D. Amyloid hypothesis deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991;12: 383-388.
-
(1991)
Trends Pharmacol Sci
, vol.12
, pp. 383-388
-
-
Hardy, J.1
Akksop, D.2
-
28
-
-
33847662852
-
Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide
-
Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101-112.
-
(2007)
Nat Rev Mol Cell Biol
, vol.8
, pp. 101-112
-
-
Haass, C.1
Selkoe, D.J.2
-
29
-
-
33644592598
-
Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study
-
Watson GS, Cholerton BA, Reger MA, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005;13:950-958.
-
(2005)
Am J Geriatr Psychiatry
, vol.13
, pp. 950-958
-
-
Watson, G.S.1
Cholerton, B.A.2
Reger, M.A.3
-
30
-
-
77956090575
-
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: Results from a randomized, double-blind, placebo-controlled phase III study
-
Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010;30:131-146.
-
(2010)
Dement Geriatr Cogn Disord
, vol.30
, pp. 131-146
-
-
Gold, M.1
Alderton, C.2
Zvartau-Hind, M.3
-
31
-
-
84889601493
-
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738) (EPOCH
-
Merck, Bethesda, MD: US National Library of Medicine, updated November 4, 2013], Accessed November 22, 2013
-
Merck. An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738) (EPOCH). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated November 4, 2013]. Available from: urlhttp://www.clinicaltrials.gov/ct2/show/NCT01739348?term=MK-8931&rank=2. NLM identifier: NCT01739348. Accessed November 22, 2013.
-
(2012)
ClinicalTrials.gov [website On the Internet]
-
-
-
32
-
-
84889590080
-
Efficacy and Safety Trial of MK-8931 in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)
-
Merck, Bethesda, MD: US National Library of Medicine, updated November 19, 2013]. Available from, Accessed November 22, 2013
-
Merck. Efficacy and Safety Trial of MK-8931 in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS). In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2013 [updated November 19, 2013]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01953601?term=MK-8931&rank=3. NLM identifier: NCT01953601. Accessed November 22, 2013.
-
(2013)
ClinicalTrials.gov [website On the Internet]
-
-
-
33
-
-
33750151419
-
Assembly, trafficking and function of gamma-secretase
-
Kaether C, Haass C, Steiner H. Assembly, trafficking and function of gamma-secretase. Neurodegener Dis. 2006;3:275-283.
-
(2006)
Neurodegener Dis
, vol.3
, pp. 275-283
-
-
Kaether, C.1
Haass, C.2
Steiner, H.3
-
34
-
-
66349133387
-
Secretase inhibitors and modulators for Alzheimer's disease treatment
-
Tomita T. Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev Neurother. 2009;9:661-679.
-
(2009)
Expert Rev Neurother
, vol.9
, pp. 661-679
-
-
Tomita, T.1
-
35
-
-
66749084437
-
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system
-
Bateman RJ, Siemers ER, Mawuenyega KG, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009;66:48-54.
-
(2009)
Ann Neurol
, vol.66
, pp. 48-54
-
-
Bateman, R.J.1
Siemers, E.R.2
Mawuenyega, K.G.3
-
36
-
-
79952529991
-
What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us
-
Schor NF. What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us. Ann Neurol. 2011;69:237-239.
-
(2011)
Ann Neurol
, vol.69
, pp. 237-239
-
-
Schor, N.F.1
-
37
-
-
84872320528
-
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects
-
Dockens R, Wang JS, Castaneda L, et al. A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects. Clin Pharmacokinet. 2012;51:681-693.
-
(2012)
Clin Pharmacokinet
, vol.51
, pp. 681-693
-
-
Dockens, R.1
Wang, J.S.2
Castaneda, L.3
-
38
-
-
0033536163
-
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
-
Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-177.
-
(1999)
Nature
, vol.400
, pp. 173-177
-
-
Schenk, D.1
Barbour, R.2
Dunn, W.3
-
39
-
-
20944448555
-
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial
-
Gilman S, Koller M, Black RS. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553-1562.
-
(2005)
Neurology
, vol.64
, pp. 1553-1562
-
-
Gilman, S.1
Koller, M.2
Black, R.S.3
-
40
-
-
47149112621
-
Long-term effect of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial
-
Holmes C, Boche D, Wilkinson D, et al. Long-term effect of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216-223.
-
(2008)
Lancet
, vol.372
, pp. 216-223
-
-
Holmes, C.1
Boche, D.2
Wilkinson, D.3
-
41
-
-
84862331908
-
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: Randomised, double-blind, placebo-controlled, first-in-human study
-
Winblad B, Andreasen N, Minthon L, et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012;11: 597-604.
-
(2012)
Lancet Neurol
, vol.11
, pp. 597-604
-
-
Winblad, B.1
Andreasen, N.2
Minthon, L.3
-
42
-
-
84884910087
-
Immunotherapy against amyloid pathology in Alzheimer's disease
-
Galimberti D, Ghezzi L, Scarpini E. Immunotherapy against amyloid pathology in Alzheimer's disease. J Neurol Sci. 2013;333:50-54.
-
(2013)
J Neurol Sci
, vol.333
, pp. 50-54
-
-
Galimberti, D.1
Ghezzi, L.2
Scarpini, E.3
-
43
-
-
84874138659
-
Bapineuzumab, an investigational agent for Alzheimer's disease
-
Khorassani F, Hilas O. Bapineuzumab, an investigational agent for Alzheimer's disease. P T. 2013;38:89-91.
-
(2013)
P T
, vol.38
, pp. 89-91
-
-
Khorassani, F.1
Hilas, O.2
-
44
-
-
84877254025
-
Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
-
Moreth J, Mavoungou C, Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer's disease: what are the most promising targets? Immun Ageing. 2013;10:18.
-
(2013)
Immun Ageing
, vol.10
, pp. 18
-
-
Moreth, J.1
Mavoungou, C.2
Schindowski, K.3
-
45
-
-
79961230030
-
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease
-
Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011;68:853-861.
-
(2011)
Arch Gen Psychiatry
, vol.68
, pp. 853-861
-
-
Tariot, P.N.1
Schneider, L.S.2
Cummings, J.3
-
46
-
-
79955546563
-
Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial
-
Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011;198:351-356.
-
(2011)
Br J Psychiatry
, vol.198
, pp. 351-356
-
-
Forlenza, O.V.1
Diniz, B.S.2
Radanovic, M.3
Santos, F.S.4
Talib, L.L.5
Gattaz, W.F.6
-
47
-
-
34250615440
-
NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: Potential therapeutic role in brain disorders
-
Luna-Medina R, Cortes-Canteli M, Sanchez-Galiano S, et al. NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders. J Neurosci. 2007;27:5766-5776.
-
(2007)
J Neurosci
, vol.27
, pp. 5766-5776
-
-
Luna-Medina, R.1
Cortes-Canteli, M.2
Sanchez-Galiano, S.3
-
48
-
-
77953518555
-
Alzheimer's disease: Clinical trials and drug development
-
Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010;9:702-716.
-
(2010)
Lancet Neurol
, vol.9
, pp. 702-716
-
-
Mangialasche, F.1
Solomon, A.2
Winblad, B.3
Mecocci, P.4
Kivipelto, M.5
-
49
-
-
84878127734
-
A phase 2, double-blind, placebo-controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment
-
Morimoto BH, Schmechel D, Hirman J, et al. A phase 2, double-blind, placebo-controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Dement Geriatr Cogn Disord. 2013;35:325-336.
-
(2013)
Dement Geriatr Cogn Disord
, vol.35
, pp. 325-336
-
-
Morimoto, B.H.1
Schmechel, D.2
Hirman, J.3
-
50
-
-
58149267462
-
Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau
-
Green KN, Steffan JS, Martinez-Coria H, et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci. 2008;28:11500-11510.
-
(2008)
J Neurosci
, vol.28
, pp. 11500-11510
-
-
Green, K.N.1
Steffan, J.S.2
Martinez-Coria, H.3
|